ALX Oncology Holdings宣布,其评估Evorpacept与Zanidatamab联合疗法治疗晚期乳腺癌的临床试验中获得的CD47生物标志物数据,将于2026年欧洲肿瘤内科学会乳腺癌年会正式发布。这一突破性研究将为靶向CD47通路在乳腺癌领域的应用提供关键临床依据。
ALX Oncology Holdings宣布,其评估Evorpacept与Zanidatamab联合疗法治疗晚期乳腺癌的临床试验中获得的CD47生物标志物数据,将于2026年欧洲肿瘤内科学会乳腺癌年会正式发布。这一突破性研究将为靶向CD47通路在乳腺癌领域的应用提供关键临床依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.